Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Should FDA Approval of Extended EYLEA HD Dosing Flexibility Require Action From Regeneron Pharmaceuticals (REGN) Investors?
11.04.2026 15:16
In early April 2026, Regeneron Pharmaceuticals received U.S. FDA approval to extend EYLEA HD dosing intervals up to every 20 weeks for wet age-related macular degeneration and diabetic macular edema, supported by 96-week efficacy and safety data from the pivotal PULSAR and PHOTON trials. This label expansion could meaningfully reduce treatment burden for many retinal patients while broadening EYLEA HD’s flexibility compared with other injectable anti-VEGF therapies. We’ll now examine how...
REGN or ILMN: Which Is the Better Value Stock Right Now?
09.04.2026 15:40
REGN vs. ILMN: Which Stock Is the Better Value Option?
Bernstein Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $921
08.04.2026 09:36
Bernstein analyst William Pickering maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and lowers the price target from $925 to $921.
Regeneron Pharma Now Expects Q1 GAAP And Non-GAAP Results To Include Acquired IPR&D Charge Of ~$102M On Pre-Tax Basis
08.04.2026 07:14
-SEC Filing
Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists
04.04.2026 03:12
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema. The updated label allows eligible patients to receive injections as infrequently as every 20 weeks after one year of successful treatment. The decision is supported by 96 week efficacy and safety data and expands EYLEA HD dosing flexibility compared with other anti VEGF options. For investors watching Regeneron...
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
03.04.2026 16:10
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
03.04.2026 00:08
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
02.04.2026 19:41
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy
02.04.2026 18:29
Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
02.04.2026 16:00
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen allows patients with wAMD and DME to be treated as infrequently as 2 to 3 times a year, further extending the widest range of dosing intervals of any approved injectable anti-VEGF TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced th
Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines
27.03.2026 12:01
Kodiak Sciences Inc. jumps on Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy. Click for this KOD stock update and a look at recent results and valuation.
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
27.03.2026 11:56
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
27.03.2026 08:54
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
AstraZeneca Strengthens Position In COPD Race With Successful Trials
27.03.2026 08:46
AstraZeneca reports Phase 3 success for tozorakimab in COPD, reducing exacerbations and showing strong safety across broad patient groups.
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone
24.03.2026 10:54
Apogee Therapeutics, Inc. Strong Buy: zumilokibart AD data supports Q3M/Q6M dosing, key 2026 catalysts and strong cash runwayâread now. Click for this APGE update.
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24.03.2026 06:00
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved ind
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24.03.2026 06:00
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,
Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid
24.03.2026 02:16
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic,
Assessing Illumina (ILMN) Valuation After Expanded Genomics And Proteomics Alliance With Regeneron
15.03.2026 11:08
Illumina (ILMN) is back in focus after expanding its Alliance for Genomic Discovery with Regeneron Genetics Center and launching a dataset of more than 50,000 genomes plus proteomic data using Illumina Protein Prep, targeting multiomic drug discovery research. See our latest analysis for Illumina. Despite the latest alliance news, Illumina’s share price at US$118.94 reflects mixed momentum, with a 2.92% 1 day share price return but a 90 day share price return decline of 11.84%. The 1 year...
3 Profitable Stocks We Think Twice About
13.03.2026 15:31
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.